



# Delivering Tomorrow's Treatments Today:

## Supporting cancer treatment access and innovation

US Oncology Research is dedicated to bringing the latest cancer treatment options to patients in the community setting by delivering high quality solutions that help you efficiently address the complexities involved in executing clinical trials in the community. Through affiliated research practices in The US Oncology Network, patients have access to the latest treatments and clinical trial options close to home.

## SCALE

The US Oncology Network facilitates treatment for 850,000 patients annually, delivering the latest in treatments and care.

## TECHNOLOGY

Our technology platform drives consistency and efficiency across all research sites. We leverage EHR and Clinical Trial Management systems to support patient identification, enrollment and trial outcomes.

## EXPERTISE

Our affiliated investigators and research staff span every cancer type and have contributed to some of the most important developments in cancer treatment, including participation in the pivotal trial for one third of all FDA approved treatments.

### Research with a Patient Centric Approach

Our network of 1,400 physicians and clinical staff across approximately 60 research sites and 160 locations are experts in community oncology. Since 1999 more than 66,000 patients have participated in approximately 1,500 clinical trials in affiliated research practices. Additionally, US Oncology Research has become one of the premier Phase I programs in the nation with more than 2,000 patients enrolled in 150 Phase I studies since 2006.

### Operational Excellence

Operational excellence is at the core of every clinical trial we execute. Our central team executes one budget, one IRB review and one contract on behalf of all participating sites. In addition, USOR has their own central IRB and Investigational Product Center enabling compliant and expeditious operations with an approximate study start-up time of 12 weeks from submission of all critical documents.

Our innovative STAR (Select Trial for Accelerated Rollout) model opens a trial upon patient identification—enabling rapid study start up by bringing the trial to the patient rather than sending the patient to a less convenient, limited network location.

## Learn More

[researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)

(281) 863-1000